for all
for all
for all
Fluorion Covidenza kit has been developed for the detection and discrimination of SARS-CoV-2, Influenza A and Influenza B viruses from RNA samples obtained from patients.
The positive control in the kit is synthetic DNA. It contains target regions of the N1, N2, M2, NS1 and RNAseP genes that are amplified only with the primer-probe sets included in this kit. The content of the positive control tube is not infectious.
Fluorion Covidenza +, developed for Qualitative detection and discrimination of Coronavirus 2019 (COVID-19) SARS CoV-2, Influenza A, Influenza B, RSV and Rhinovirus viruses in patients with COVID-19, influenza or common cold like symptoms (e.g. fever, cough, shortness of breath), using lower respiratory tract (bronchoalveolar lavage (BAL), tracheal aspirate and/or upper respiratory tract (nasopharyngeal and oropharyngeal fluids, nasal swab samples.)
Highlights
Why Fluorion Covidenza or Covidenza+
Testing is one of the most crucial steps in tackling the Coronavirus pandemic, which is why we have developed the Fluorion Covidenza Kit. The kit has been developed for the detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viruses from swab samples obtained from patients.
Compatible with variety of extraction platforms and PCR instruments
Quick extraction available
Multiplex Real-Time PCR
Accurate internal and positive controls
One sample per patient for all parameters
High specificity
High sensitivity (30 copies/reaction)
Professional’s opinion
Not every respiratory infection is Covid. The right diagnosis is the critical requirement for proper treatment. Evidence-based treatment based on PCR tests, is our most important tool against respiratory tract infectious diseases. Fast, Easy, Accessible.
Have questions about
Fluorion Covidenza?
We love to hear from you about your questions, comments and anything related to our products and services.
Please do not hesitate to drop us a message and we will get back to you as soon as possible.
for all
for all
for all
Fluorion Covidenza kit has been developed for the detection and discrimination of SARS-CoV-2, Influenza A and Influenza B viruses from swab samples obtained from patients.
The positive control in the kit is synthetic DNA. It contains target regions of the N1, N2, M2, NS1 and RNAseP genes that are amplified only with the primer-probe sets included in this kit. The content of the positive control tube is not infectious.
Fluorion Covidenza +, developed for Qualitative detection and discrimination of Coronavirus 2019 (COVID-19) SARS CoV-2, Influenza A, Influenza B, RSV and Rhinovirus viruses in patients with COVID-19, influenza or common cold like symptoms (e.g. fever, cough, shortness of breath), using lower respiratory tract (bronchoalveolar lavage (BAL), tracheal aspirate and/or upper respiratory tract (nasopharyngeal and oropharyngeal fluids, nasal swab samples.)
Highlights
Why Fluorion Covidenza or Covidenza+
Testing is one of the most crucial steps in tackling the Coronavirus pandemic, which is why we have developed the Fluorion Covidenza Kit. The kit has been developed for the detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viruses from swab samples obtained from patients
Compatible with variety of extraction platforms and PCR instruments
Quick extraction available
Multiplex Real-Time PCR
Accurate internal and positive controls
One sample per patient for all parameters
High specificity
High sensitivity (30 copies/reaction)
Professional’s opinion
Not every respiratory infection is Covid. The right diagnosis is the critical requirement for proper treatment. Evidence-based treatment based on PCR tests, is our most important tool against respiratory tract infectious diseases. Fast, Easy, Accessible.
Have questions about
Fluorion Covidenza?
We love to hear from you about your questions, comments and anything related to our products and services.
Please do not hesitate to drop us a message and we will get back to you as soon as possible.
